1 Report Business Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Icotinib
        1.2.3 Gefitinib
        1.2.4 Erlotinib
        1.2.5 Afatinib
        1.2.6 Osimertinib
        1.2.7 Brigatinib
        1.2.8 Other
    1.3 Market by Application
        1.3.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Squamous Cell Carcinoma of NSCLC
        1.3.3 Adenocarcinoma of NSCLC
        1.3.4 Large Cell Carcinoma of NSCLC
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Perspective (2017-2028)
    2.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Growth Trends by Region
        2.2.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Historic Market Size by Region (2017-2022)
        2.2.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Region (2023-2028)
    2.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Dynamics
        2.3.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Industry Trends
        2.3.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Drivers
        2.3.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Challenges
        2.3.4 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Players by Revenue
        3.1.1 Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Players by Revenue (2017-2022)
        3.1.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Players (2017-2022)
    3.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue
    3.4 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Concentration Ratio
        3.4.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue in 2021
    3.5 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players Head office and Area Served
    3.6 Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Product Solution and Service
    3.7 Date of Enter into Targeted Drug EGFR RTK Inhibitors for NSCLC Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Targeted Drug EGFR RTK Inhibitors for NSCLC Breakdown Data by Type
    4.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Historic Market Size by Type (2017-2022)
    4.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Type (2023-2028)
5 Targeted Drug EGFR RTK Inhibitors for NSCLC Breakdown Data by Application
    5.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Historic Market Size by Application (2017-2022)
    5.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2017-2028)
    6.2 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
        6.2.1 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2017-2022)
        6.2.2 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2023-2028)
        6.2.3 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2017-2028)
    6.3 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application
        6.3.1 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2017-2022)
        6.3.2 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2023-2028)
        6.3.3 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2017-2028)
    6.4 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country
        6.4.1 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2017-2022)
        6.4.2 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2023-2028)
        6.4.3 U.S.
        6.4.4 Canada
7 Europe
    7.1 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2017-2028)
    7.2 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
        7.2.1 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2017-2022)
        7.2.2 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2023-2028)
        7.2.3 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2017-2028)
    7.3 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application
        7.3.1 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2017-2022)
        7.3.2 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2023-2028)
        7.3.3 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2017-2028)
    7.4 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country
        7.4.1 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2017-2022)
        7.4.2 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2023-2028)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2017-2028)
    8.2 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
        8.2.1 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2017-2022)
        8.2.2 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2023-2028)
        8.2.3 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2017-2028)
    8.3 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application
        8.3.1 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2017-2022)
        8.3.2 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2023-2028)
        8.3.3 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2017-2028)
    8.4 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region
        8.4.1 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2017-2022)
        8.4.2 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2023-2028)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia 
9 Latin America
    9.1 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2017-2028)
    9.2 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
        9.2.1 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2017-2022)
        9.2.2 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2023-2028)
        9.2.3 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2017-2028)
    9.3 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application
        9.3.1 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2017-2022)
        9.3.2 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2023-2028)
        9.3.3 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2017-2028)
    9.4 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country
        9.4.1 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2017-2022)
        9.4.2 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2023-2028)
        9.4.3 Mexico
        9.4.4 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2017-2028)
    10.2 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
        10.2.1 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2017-2022)
        10.2.2 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2023-2028)
        10.2.3 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2017-2028)
    10.3 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application
        10.3.1 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2017-2022)
        10.3.2 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2023-2028)
        10.3.3 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2017-2028)
    10.4 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country
        10.4.1 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2017-2022)
        10.4.2 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2023-2028)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE
11 Key Players Profiles
    11.1 Beta Pharma
        11.1.1 Beta Pharma Company Details
        11.1.2 Beta Pharma Business Overview
        11.1.3 Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.1.4 Beta Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.1.5 Beta Pharma Recent Developments
    11.2 AstraZeneca
        11.2.1 AstraZeneca Company Details
        11.2.2 AstraZeneca Business Overview
        11.2.3 AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.2.4 AstraZeneca Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.2.5 AstraZeneca Recent Developments
    11.3 Natco Pharma
        11.3.1 Natco Pharma Company Details
        11.3.2 Natco Pharma Business Overview
        11.3.3 Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.3.4 Natco Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.3.5 Natco Pharma Recent Developments
    11.4 Qilu Pharmaceutical
        11.4.1 Qilu Pharmaceutical Company Details
        11.4.2 Qilu Pharmaceutical Business Overview
        11.4.3 Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.4.4 Qilu Pharmaceutical Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.4.5 Qilu Pharmaceutical Recent Developments
    11.5 Genentech (Roche Group)
        11.5.1 Genentech (Roche Group) Company Details
        11.5.2 Genentech (Roche Group) Business Overview
        11.5.3 Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.5.4 Genentech (Roche Group) Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.5.5 Genentech (Roche Group) Recent Developments
    11.6 Mylan
        11.6.1 Mylan Company Details
        11.6.2 Mylan Business Overview
        11.6.3 Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.6.4 Mylan Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.6.5 Mylan Recent Developments
    11.7 Teva
        11.7.1 Teva Company Details
        11.7.2 Teva Business Overview
        11.7.3 Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.7.4 Teva Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.7.5 Teva Recent Developments
    11.8 OSI Pharmaceuticals
        11.8.1 OSI Pharmaceuticals Company Details
        11.8.2 OSI Pharmaceuticals Business Overview
        11.8.3 OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.8.4 OSI Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.8.5 OSI Pharmaceuticals Recent Developments
    11.9 Glenmark Pharmaceuticals
        11.9.1 Glenmark Pharmaceuticals Company Details
        11.9.2 Glenmark Pharmaceuticals Business Overview
        11.9.3 Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.9.4 Glenmark Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.9.5 Glenmark Pharmaceuticals Recent Developments
    11.10 Beacon Pharmaceuticals
        11.10.1 Beacon Pharmaceuticals Company Details
        11.10.2 Beacon Pharmaceuticals Business Overview
        11.10.3 Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.10.4 Beacon Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.10.5 Beacon Pharmaceuticals Recent Developments
    11.11 Boehringer Ingelheim
        11.11.1 Boehringer Ingelheim Company Details
        11.11.2 Boehringer Ingelheim Business Overview
        11.11.3 Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.11.4 Boehringer Ingelheim Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.11.5 Boehringer Ingelheim Recent Developments
    11.12 Pfizer
        11.12.1 Pfizer Company Details
        11.12.2 Pfizer Business Overview
        11.12.3 Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.12.4 Pfizer Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.12.5 Pfizer Recent Developments
    11.13 ARIAD Pharmaceuticals (Takeda)
        11.13.1 ARIAD Pharmaceuticals (Takeda) Company Details
        11.13.2 ARIAD Pharmaceuticals (Takeda) Business Overview
        11.13.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.13.4 ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.13.5 ARIAD Pharmaceuticals (Takeda) Recent Developments
    11.14 Genvio Pharma Limited
        11.14.1 Genvio Pharma Limited Company Details
        11.14.2 Genvio Pharma Limited Business Overview
        11.14.3 Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.14.4 Genvio Pharma Limited Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.14.5 Genvio Pharma Limited Recent Developments
    11.15 Drug International Limted
        11.15.1 Drug International Limted Company Details
        11.15.2 Drug International Limted Business Overview
        11.15.3 Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.15.4 Drug International Limted Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.15.5 Drug International Limted Recent Developments
    11.16 Everest Pharmaceuticals
        11.16.1 Everest Pharmaceuticals Company Details
        11.16.2 Everest Pharmaceuticals Business Overview
        11.16.3 Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.16.4 Everest Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.16.5 Everest Pharmaceuticals Recent Developments
    11.17 Incepta Pharmaceuticals Limited
        11.17.1 Incepta Pharmaceuticals Limited Company Details
        11.17.2 Incepta Pharmaceuticals Limited Business Overview
        11.17.3 Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.17.4 Incepta Pharmaceuticals Limited Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.17.5 Incepta Pharmaceuticals Limited Recent Developments
    11.18 Cipla Pharma
        11.18.1 Cipla Pharma Company Details
        11.18.2 Cipla Pharma Business Overview
        11.18.3 Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.18.4 Cipla Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.18.5 Cipla Pharma Recent Developments
    11.19 Dr Reddy's Laboratories
        11.19.1 Dr Reddy's Laboratories Company Details
        11.19.2 Dr Reddy's Laboratories Business Overview
        11.19.3 Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.19.4 Dr Reddy's Laboratories Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.19.5 Dr Reddy's Laboratories Recent Developments
    11.20 Zydus Cadila
        11.20.1 Zydus Cadila Company Details
        11.20.2 Zydus Cadila Business Overview
        11.20.3 Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.20.4 Zydus Cadila Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.20.5 Zydus Cadila Recent Developments
    11.21 Hetero Drugs
        11.21.1 Hetero Drugs Company Details
        11.21.2 Hetero Drugs Business Overview
        11.21.3 Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.21.4 Hetero Drugs Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.21.5 Hetero Drugs Recent Developments
    11.22 Intas Pharmaceuticals
        11.22.1 Intas Pharmaceuticals Company Details
        11.22.2 Intas Pharmaceuticals Business Overview
        11.22.3 Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.22.4 Intas Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.22.5 Intas Pharmaceuticals Recent Developments
    11.23 Alkem Laboratories
        11.23.1 Alkem Laboratories Company Details
        11.23.2 Alkem Laboratories Business Overview
        11.23.3 Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.23.4 Alkem Laboratories Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.23.5 Alkem Laboratories Recent Developments
    11.24 RPG Life Sciences
        11.24.1 RPG Life Sciences Company Details
        11.24.2 RPG Life Sciences Business Overview
        11.24.3 RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.24.4 RPG Life Sciences Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.24.5 RPG Life Sciences Recent Developments
    11.25 Fresenius Kabi India
        11.25.1 Fresenius Kabi India Company Details
        11.25.2 Fresenius Kabi India Business Overview
        11.25.3 Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
        11.25.4 Fresenius Kabi India Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
        11.25.5 Fresenius Kabi India Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Author Details
    13.3 Disclaimer
                  
              

                

                 
List of Tables
    Table 1. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
    Table 2. Key Players of Icotinib
    Table 3. Key Players of Gefitinib
    Table 4. Key Players of Erlotinib
    Table 5. Key Players of Afatinib
    Table 6. Key Players of Osimertinib
    Table 7. Key Players of Brigatinib
    Table 8. Key Players of Other
    Table 9. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
    Table 10. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 11. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2017-2022) & (US$ Million)
    Table 12. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Region (2017-2022)
    Table 13. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 14. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Region (2023-2028)
    Table 15. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Trends
    Table 16. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Drivers
    Table 17. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Challenges
    Table 18. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Restraints
    Table 19. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Players (2017-2022) & (US$ Million)
    Table 20. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Share by Players (2017-2022)
    Table 21. Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC as of 2021)
    Table 22. Ranking of Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Companies by Revenue (US$ Million) in 2021
    Table 23. Global 5 Largest Players Market Share by Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (CR5 and HHI) & (2017-2022)
    Table 24. Key Players Headquarters and Area Served
    Table 25. Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Product Solution and Service
    Table 26. Date of Enter into Targeted Drug EGFR RTK Inhibitors for NSCLC Market
    Table 27. Mergers & Acquisitions, Expansion Plans
    Table 28. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2017-2022) & (US$ Million)
    Table 29. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Type (2017-2022)
    Table 30. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 31. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Type (2023-2028)
    Table 32. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2017-2022) & (US$ Million)
    Table 33. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Share by Application (2017-2022)
    Table 34. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 35. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Share by Application (2023-2028)
    Table 36. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2017-2022) & (US$ Million)
    Table 37. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2023-2028) & (US$ Million)
    Table 38. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2017-2022) & (US$ Million)
    Table 39. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2023-2028) & (US$ Million)
    Table 40. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2017-2022) & (US$ Million)
    Table 41. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2023-2028) & (US$ Million)
    Table 42. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2017-2022) & (US$ Million)
    Table 43. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2023-2028) & (US$ Million)
    Table 44. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2017-2022) & (US$ Million)
    Table 45. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2023-2028) & (US$ Million)
    Table 46. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2017-2022) & (US$ Million)
    Table 47. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2023-2028) & (US$ Million)
    Table 48. Asia Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2017-2022) & (US$ Million)
    Table 49. Asia Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2023-2028) & (US$ Million)
    Table 50. Asia Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2017-2022) & (US$ Million)
    Table 51. Asia Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2023-2028) & (US$ Million)
    Table 52. Asia Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2017-2022) & (US$ Million)
    Table 53. Asia Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2023-2028) & (US$ Million)
    Table 54. Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2017-2022) & (US$ Million)
    Table 55. Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2023-2028) & (US$ Million)
    Table 56. Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2017-2022) & (US$ Million)
    Table 57. Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2023-2028) & (US$ Million)
    Table 58. Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2017-2022) & (US$ Million)
    Table 59. Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2023-2028) & (US$ Million)
    Table 60. Middle East and Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2017-2022) & (US$ Million)
    Table 61. Middle East and Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2023-2028) & (US$ Million)
    Table 62. Middle East and Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2017-2022) & (US$ Million)
    Table 63. Middle East and Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2023-2028) & (US$ Million)
    Table 64. Middle East and Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2017-2022) & (US$ Million)
    Table 65. Middle East and Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2023-2028) & (US$ Million)
    Table 66. Beta Pharma Company Details
    Table 67. Beta Pharma Business Overview
    Table 68. Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 69. Beta Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 70. Beta Pharma Recent Developments
    Table 71. AstraZeneca Company Details
    Table 72. AstraZeneca Business Overview
    Table 73. AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 74. AstraZeneca Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 75. AstraZeneca Recent Developments
    Table 76. Natco Pharma Company Details
    Table 77. Natco Pharma Business Overview
    Table 78. Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 79. Natco Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 80. Natco Pharma Recent Developments
    Table 81. Qilu Pharmaceutical Company Details
    Table 82. Qilu Pharmaceutical Business Overview
    Table 83. Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 84. Qilu Pharmaceutical Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 85. Qilu Pharmaceutical Recent Developments
    Table 86. Genentech (Roche Group) Company Details
    Table 87. Genentech (Roche Group) Business Overview
    Table 88. Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 89. Genentech (Roche Group) Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 90. Genentech (Roche Group) Recent Developments
    Table 91. Mylan Company Details
    Table 92. Mylan Business Overview
    Table 93. Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 94. Mylan Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 95. Mylan Recent Developments
    Table 96. Teva Company Details
    Table 97. Teva Business Overview
    Table 98. Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 99. Teva Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 100. Teva Recent Developments
    Table 101. OSI Pharmaceuticals Company Details
    Table 102. OSI Pharmaceuticals Business Overview
    Table 103. OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 104. OSI Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 105. OSI Pharmaceuticals Recent Developments
    Table 106. Glenmark Pharmaceuticals Company Details
    Table 107. Glenmark Pharmaceuticals Business Overview
    Table 108. Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 109. Glenmark Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 110. Glenmark Pharmaceuticals Recent Developments
    Table 111. Beacon Pharmaceuticals Company Details
    Table 112. Beacon Pharmaceuticals Business Overview
    Table 113. Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 114. Beacon Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 115. Beacon Pharmaceuticals Recent Developments
    Table 116. Boehringer Ingelheim Company Details
    Table 117. Boehringer Ingelheim Business Overview
    Table 118. Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 119. Boehringer Ingelheim Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 120. Boehringer Ingelheim Recent Developments
    Table 121. Pfizer Company Details
    Table 122. Pfizer Business Overview
    Table 123. Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 124. Pfizer Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 125. Pfizer Recent Developments
    Table 126. ARIAD Pharmaceuticals (Takeda) Company Details
    Table 127. ARIAD Pharmaceuticals (Takeda) Business Overview
    Table 128. ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 129. ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 130. ARIAD Pharmaceuticals (Takeda) Recent Developments
    Table 131. Genvio Pharma Limited Company Details
    Table 132. Genvio Pharma Limited Business Overview
    Table 133. Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 134. Genvio Pharma Limited Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 135. Genvio Pharma Limited Recent Developments
    Table 136. Drug International Limted Company Details
    Table 137. Drug International Limted Business Overview
    Table 138. Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 139. Drug International Limted Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 140. Drug International Limted Recent Developments
    Table 141. Everest Pharmaceuticals Company Details
    Table 142. Everest Pharmaceuticals Business Overview
    Table 143. Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 144. Everest Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 145. Everest Pharmaceuticals Recent Developments
    Table 146. Incepta Pharmaceuticals Limited Company Details
    Table 147. Incepta Pharmaceuticals Limited Business Overview
    Table 148. Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 149. Incepta Pharmaceuticals Limited Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 150. Incepta Pharmaceuticals Limited Recent Developments
    Table 151. Cipla Pharma Company Details
    Table 152. Cipla Pharma Business Overview
    Table 153. Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 154. Cipla Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 155. Cipla Pharma Recent Developments
    Table 156. Dr Reddy's Laboratories Company Details
    Table 157. Dr Reddy's Laboratories Business Overview
    Table 158. Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 159. Dr Reddy's Laboratories Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 160. Dr Reddy's Laboratories Recent Developments
    Table 161. Zydus Cadila Company Details
    Table 162. Zydus Cadila Business Overview
    Table 163. Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 164. Zydus Cadila Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 165. Zydus Cadila Recent Developments
    Table 166. Hetero Drugs Company Details
    Table 167. Hetero Drugs Business Overview
    Table 168. Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 169. Hetero Drugs Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 170. Hetero Drugs Recent Developments
    Table 171. Intas Pharmaceuticals Company Details
    Table 172. Intas Pharmaceuticals Business Overview
    Table 173. Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 174. Intas Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 175. Intas Pharmaceuticals Recent Developments
    Table 176. Alkem Laboratories Company Details
    Table 177. Alkem Laboratories Business Overview
    Table 178. Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 179. Alkem Laboratories Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 180. Alkem Laboratories Recent Developments
    Table 181. RPG Life Sciences Company Details
    Table 182. RPG Life Sciences Business Overview
    Table 183. RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 184. RPG Life Sciences Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 185. RPG Life Sciences Recent Developments
    Table 186. Fresenius Kabi India Company Details
    Table 187. Fresenius Kabi India Business Overview
    Table 188. Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 189. Fresenius Kabi India Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 190. Fresenius Kabi India Recent Developments
    Table 191. Research Programs/Design for This Report
    Table 192. Key Data Information from Secondary Sources
    Table 193. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type: 2021 VS 2028
    Figure 2. Icotinib Features
    Figure 3. Gefitinib Features
    Figure 4. Erlotinib Features
    Figure 5. Afatinib Features
    Figure 6. Osimertinib Features
    Figure 7. Brigatinib Features
    Figure 8. Other Features
    Figure 9. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application: 2021 VS 2028
    Figure 10. Squamous Cell Carcinoma of NSCLC Case Studies
    Figure 11. Adenocarcinoma of NSCLC Case Studies
    Figure 12. Large Cell Carcinoma of NSCLC Case Studies
    Figure 13. Targeted Drug EGFR RTK Inhibitors for NSCLC Report Years Considered
    Figure 14. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 15. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 16. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Region: 2021 VS 2028
    Figure 17. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Players in 2021
    Figure 18. Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC as of 2021)
    Figure 19. The Top 10 and 5 Players Market Share by Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue in 2021
    Figure 20. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY (2017-2028) & (US$ Million)
    Figure 21. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2017-2028)
    Figure 22. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2017-2028)
    Figure 23. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Share by Country (2017-2028)
    Figure 24. United States Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 25. Canada Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 26. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY (2017-2028) & (US$ Million)
    Figure 27. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2017-2028)
    Figure 28. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2017-2028)
    Figure 29. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Share by Country (2017-2028)
    Figure 30. Germany Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. France Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. U.K. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. Italy Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. Russia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 35. Nordic Countries Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 36. Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY (2017-2028) & (US$ Million)
    Figure 37. Asia Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2017-2028)
    Figure 38. Asia Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2017-2028)
    Figure 39. Asia Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Share by Region (2017-2028)
    Figure 40. China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. South Korea Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 43. Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 44. India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 45. Australia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
    Figure 46. Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY (2017-2028) & (US$ Million)
    Figure 47. Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2017-2028)
    Figure 48. Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2017-2028)
    Figure 49. Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Share by Country (2017-2028)
    Figure 50. Mexico Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 51. Brazil Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 52. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY (2017-2028) & (US$ Million)
    Figure 53. Middle East and Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2017-2028)
    Figure 54. Middle East and Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2017-2028)
    Figure 55. Middle East and Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Share by Country (2017-2028)
    Figure 56. Turkey Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 57. Saudi Arabia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 58. UAE Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 59. Beta Pharma Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 60. AstraZeneca Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 61. Natco Pharma Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 62. Qilu Pharmaceutical Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 63. Genentech (Roche Group) Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 64. Mylan Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 65. Teva Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 66. OSI Pharmaceuticals Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 67. Glenmark Pharmaceuticals Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 68. Beacon Pharmaceuticals Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 69. Boehringer Ingelheim Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 70. Pfizer Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 71. ARIAD Pharmaceuticals (Takeda) Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 72. Genvio Pharma Limited Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 73. Drug International Limted Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 74. Everest Pharmaceuticals Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 75. Incepta Pharmaceuticals Limited Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 76. Cipla Pharma Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 77. Dr Reddy's Laboratories Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 78. Zydus Cadila Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 79. Hetero Drugs Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 80. Intas Pharmaceuticals Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 81. Alkem Laboratories Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 82. RPG Life Sciences Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 83. Fresenius Kabi India Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 84. Bottom-up and Top-down Approaches for This Report
    Figure 85. Data Triangulation
    Figure 86. Key Executives Interviewed